A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Dr Peter Staats, Chief Medical Officer at National Spine and Pain, Joins the Neuralace Medical Advisory Board

Company Continues its Successful Seed Round Fundraising, Building Off the First Close of $3.1M While Targeting a Total Capital Raise of $5M-$7M

What To Know

  •  Marshall Bedder, who leads the Pain Clinic team at Charlie Norwood VA Medical Center and serves as an Associate Professor and Director of the Addiction Medicine Fellowship Program at the Medical College of Georgia at Augusta University, was quoted in the VA article as saying “Some of our veterans have only needed to be treated a couple of times and have seen such durable results that they haven’t needed further treatment.
  • Neuralace Medical is thrilled to share the recent publication by Charlie Norwood VA Medical Center, which highlights the pioneering work conducted by its Pain Clinic team in adopting Axon therapy for the treatment of peripheral neuropathic pain (PNS).

In addition, the Charlie Norwood VAMC in Augusta, GA Recognizes its Pain Clinic for Spearheading First Use of the Axon Therapy Within the VA Health System

Neuralace Medical, Inc., a leading medical technology company specializing in innovative non-invasive solutions for the treatment of chronic peripheral neuropathic pain, is pleased to welcome Dr. Peter Staats, Chief Medical Officer at National Spine and Pain Centers, based in Frederick, MD., to the Neuralace Medical Advisory Board.

Dr Peter Staats brings extensive expertise to the company and will collaborate with the advisory board and Neuralace Medical to contribute valuable insights and strategic guidance. He expressed his enthusiasm for Axon Therapy, stating,

“I have seen Axon Therapy progress from an interesting project several years ago, to what is now an FDA-cleared, clinically impactful treatment. Axon Therapy is an excellent complement to conventional, implantable neuromodulation, bringing the benefits of neurostimulation to many more patients. I look forward to working alongside Drs. Sayed (KU Medical Center), Kapural (Carolina Pain Institute), and Bedder (VAMC Augusta) to support the market entry of this much-needed non-invasive approach.”

Validation of Axon Therapy’s Efficacy by Charlie Norwood VAMC

Neuralace Medical is thrilled to share the recent publication by Charlie Norwood VA Medical Center, which highlights the pioneering work conducted by its Pain Clinic team in adopting Axon therapy for the treatment of peripheral neuropathic pain (PNS). This milestone establishes Charlie Norwood VA Medical Center as the first VA Medical Center to incorporate Axon Therapy into its treatment regimen. The publication underscores the significant pain relief achieved by Axon Therapy, which has been proven to reduce the need for invasive procedures and decrease opioid usage for a substantial number of patients. Dr. Marshall Bedder, who leads the Pain Clinic team at Charlie Norwood VA Medical Center and serves as an Associate Professor and Director of the Addiction Medicine Fellowship Program at the Medical College of Georgia at Augusta University, was quoted in the VA article as saying “Some of our veterans have only needed to be treated a couple of times and have seen such durable results that they haven’t needed further treatment.” The publication can be accessed here.

This validation from the esteemed Charlie Norwood VA in Augusta further solidifies Axon Therapy as a transformative treatment option. Axon Therapy is currently undergoing evaluation at other VA and Department of Defense treatment facilities across the United States.

Keith Warner, CEO of Neuralace Medical, expressed his confidence in the company’s continued progress, stating, “Our ongoing clinical and commercial advancements will establish Neuralace Medical as a pioneering force in non-invasive neuromodulation for peripheral neuropathic pain. We are committed to improving patient outcomes, fostering collaboration with renowned institutions, and driving innovation in the field of pain management. Congratulations to my team; you should be proud of the impact you are making. I am grateful to be part of this remarkable team that has brought significant relief to many veterans, with many more to come.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

With this new investment partnership, E Tech Group expects to accelerate organic growth and acquisition to become a top system integrator in North America.
The investment will allow ROM InWest to further distribute its fall detection product globally.
Nawal Ouzren, Sensorion’s Chief Executive Officer, said: “We are thrilled to announce another successful capital raise, securing an additional EUR 15 million to accommodate interest expressed by certain existing investors. This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months. With this new financing, we are well-positioned to accelerate our gene therapy programs, including the progression of SENS-501 through its Phase 1/2 clinical study, Audiogene, and the advancement of our second program, GJB2-GT, towards Clinical Trial Applications submission in H1 2025. The capital increase enables the Company to finance its activities until the end of 2025. We remain deeply thankful for the ongoing support of our shareholders and partners as we strive to make a meaningful difference in the lives of those affected by hearing loss disorders.”
Strategic Investor, Osang Healthcare will partner with Kryptos Biotechnologies for the manufacturing and distribution of the product along with financing.
Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC). Obsidian Therapeutics is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.

By using this website you agree to accept Medical Device News Magazine Privacy Policy